Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

  • Technology appraisal guidance
  • TA1142
  • Published: 
Download (PDF)

Dupilumab: local formulary information

Equality impact assessment

See NICE's equality impact assessment for dupilumab for treating COPD.

This page was last updated: